UNLABELLED Direct-acting fibrin(ogen)olytic agents such as plasmin have been proved to contain effective and safety thrombolytic potential. Unfortunately, plasmin is ineffective when administered by the intravenous route because it was neutralized by plasma antiplasmin. Direct-acting fibrin(ogen)olytic agents with resistance against antiplasmin will brighten the prospect of anti-thrombosis. As ...

Cardiovascular disorders are the major cause of concern in India with estimated mortality reaching approximately 64 million by 2015. Though two major treatment options i.e. primary angioplasty (PAMI) and intravenous thrombolysis are available for the management of ST elevation myocardial infarction (STEMI), primary angioplasty is not feasible for majority of STEMI patients in India, hence early...

right-sided heart thrombus is a life-threatening condition that necessitates immediate therapy. detection of right-sided heart thrombus is usually via transthoracic echocardiography. generally, thrombolysis is considered a treatment of choice, but there is currently no consensus about the optimal therapeutic choice. we present a case of multiple right atrial thrombi with concurrent mobile and b...

To develop a more potent antithrombin agent with thrombolytic and antiplatelet properties, a new staphylokinase (SAK) variant was constructed. The kringle 2 domain (K2) of tissue type-plasminogen activator (t-PA) containing a fibrin-specific binding site (i), the RGD sequence (Arg-Gly-Asp) for the prevention of platelet aggregation (ii) and the antithrombotic agent - hirulog (iii) was assembled...

OBJECTIVE We analyzed the results of intravenous thrombolytic treatment under transesophageal echocardiographic (TEE) guidance in prosthetic valve thrombosis. BACKGROUND Thrombotic occlusion of prosthetic valves continues to be an uncommon but serious complication. Intravenous thrombolytic treatment has been proposed as an alternative to surgical intervention. METHODS In a four-year period,...

Thrombotherapy is an important approach in treatment of various diseases associated with pathologies the cardiovascular and human hemostasis systems. Screening for producers modern, specific, safe thrombolytic substances task medicine biotechnology. The aim this study was to characterize potential seven strains micromycete belonging genus Tolypocladium, which obtained from White Sea soils. Toly...

conclusions: the major barriers for thrombolytic therapy for patients with ais in this setting were delays in the provision of in-hospital services, like initial patient assessment, ct scans or laboratory studies. these results were in contrast with previous reports. background: intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (ais) and is recomme...

BACKGROUND Development of new coronary thrombolytic agents is hot in the market. A new drug, mutated recombinant tissue-type plasminogen activator (rtPAm), is the product of mutation of tPA by changing binding loci with plasminogen activator inhibitor (PAI)-1 to reduce the degradation. In vitro test has demonstrated that the activity of rtPAm is much higher than rtPA in the absence of PAI. The ...